<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">ERGOTAMINE TARTRATE <img border="0" src="../images/pr.gif"/></span><br/>(er-got'a-meen)<br/><span class="topboxtradename">Ergomar, </span><span class="topboxtradename">Ergostat<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">alpha-adrenergic antagonist (sympatholytic)</span>; <span class="classification">ergot alkaloid</span><br/><b>Pregnancy Category: </b>X<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>2 mg sublingual tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Natural amino acid alkaloid of ergot. Alpha-adrenergic blocking agent with direct stimulating action on cranial and peripheral
         vascular smooth muscles and depressant effect on central vasomotor centers. Ergotamine activity can damage vascular endothelium
         by unknown mechanism, with subsequent occlusion, thrombosis, and gangrene.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>In vascular headache, exerts vasoconstrictive action on previously dilated cerebral vessels, reduces amplitude of arterial
         pulsations, and antagonizes effects of serotonin.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>As single agent or in combination with caffeine to prevent or abort migraine, cluster headache (histamine cephalalgia), and
         other vascular headaches. Not recommended for migraine prophylaxis because of the possibility of adverse effects.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to ergotamine; sepsis, obliterative vascular disease, thromboembolic disease, prolonged use of excessive
         dosage, liver and kidney disease, severe pruritus, marked arteriosclerosis, history of MI, coronary artery disease, hypertension;
         infectious states, anemia, malnutrition; pregnancy (category X), use in children.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Lactation, older adult patients.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Vascular Headaches</span><br/><span class="rdage">Adult:</span> <span class="rdroute">SL</span> 12 mg followed by 12 mg q30min until headache abates or until max of 6 mg/24h or 10 mg/wk<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Sublingual</span><br/><ul>
<li>Instruct patient to allow sublingual (SL) tablet to dissolve under tongue and not to drink, eat, or smoke while tablet is
            in place. Do not crush SL tablets.
         </li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span>  Paresthesias; pain (spasms) of facial muscles, tongue, limbs, and lumbar region with difficulty in walking; muscle pains,
      <span class="speceff-common">weakness,</span> numbness, coldness and cyanosis of digits (Raynaud's phenomenon). <span class="typehead">Nervous System:</span> Delirium; convulsive seizures; confusion; depression; drowsiness; <span class="typehead">Digestive:</span>
<span class="speceff-common">Nausea; vomiting;</span> diarrhea; abdominal pain; unquenchable thirst; partial necrosis of tongue, disagreeable aftertaste. <span class="typehead">Cardiovascular:</span> Rapid, weak, or irregular pulse; intermittent claudication, complete absence of medium- and large-vessel pulsations in extremities;
      precordial distress and pain; angina pectoris, transient bradycardia or tachycardia; elevated or lowered BP. <span class="typehead">Skin:</span> Itching and cold skin; gangrene of nose, digits, ears. <span class="typehead">Urogenital:</span> Kidney failure. <span class="typehead">Other:</span> Symptoms of ergotism. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> With high doses of <span class="classification">beta-adrenergic blockers</span>, <span class="classification">sympathomimetics</span>, possibility of additive vasoconstrictor effects; <b>erythromycin,</b>
<b>troleandomycin</b> may cause severe peripheral vasospasm. <b>Eletriptan,</b>
<b>naratriptan,</b>
<b>rizatriptan,</b>
<b>sumatriptan, or zolmitriptan</b> may increase risk of coronary ischemia, separate drugs by 24 h; <span class="classification">azole antifungals</span> <b>(ketoconazole,</b>
<b>itraconazole,</b>
<b>fluconazole,</b>
<b>clotrimazole), </b><b>nefazodone,</b>
<b>fluoxetine,</b>
<b>fluvoxamine,</b> amprenavir, <b>delavirdine,</b>
<b>efavirenz,</b>
<b>indinavir,</b>
<b>nelfinavir,</b>
<b>ritonavir,</b>
<b>and</b>
<b>saquinavir,</b> may inhibit ergot metabolism and increase toxicity; <b>sibutramine,</b>
<b>dexfenfluramine,</b>
<b>nefazodone,</b>
<b>fluvoxamine</b> may increase risk of serotonin syndrome. <span class="typehead">Food:</span> Grapefruit juice may increase toxicity. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Variable absorption orally. <span class="typehead">Peak:</span> 0.53 h. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier. <span class="typehead">Metabolism:</span> Extensive first-pass metabolism in liver. <span class="typehead">Elimination:</span> 96% eliminated in feces; excreted in breast milk. <span class="typehead">Half-Life:</span> 2.7 h initial phase, 21 h terminal phase. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor adverse GI effects. Nausea and vomiting are adverse reactions that occur in about 10% of patients after they take
            ergotamine. Patient may need an antiemetic. Consult with physician.
         </li>
<li>Monitor patients with PVD carefully for development of peripheral ischemia.</li>
<li>Monitor long-term effectiveness. Patients receiving high ergotamine doses for prolonged periods may experience increased frequency
            of headaches, fatigue, and depression. Discontinuation of the drug in these patients results in severe withdrawal headache
            that may last a few days.
         </li>
<li>Overdose symptoms: Nausea, vomiting, weakness and pain in legs, numbness and tingling in fingers and toes, tachycardia or
            bradycardia, hypertension or hypotension, and localized edema.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Begin drug therapy as soon after onset of migraine attack as possible, preferably during migraine prodrome (scintillating
            scotomas, visual field defects, nausea, paresthesias usually on side opposite to that of the migraine).
         </li>
<li>Notify physician if migraine attacks occur more frequently or are not relieved.</li>
<li>Lie down in a quiet, dark room for 23 h after drug administration.</li>
<li>Report claudication, muscle pain or weakness of extremities, cold or numb digits, irregular heartbeat, nausea, or vomiting.
            Carefully protect extremities from exposure to cold temperatures; provide warmth, but not heat, to ischemic areas.
         </li>
<li>Do <small>NOT</small> increase dosage without consulting physician; overdosage is the chief cause of adverse effects from the drug.
         </li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>